| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2018-11-10 |
Abbvie (USA - IL) Sandoz (Switzerland) |
- intellectual property relating to Humira®
|
plaque psoriasis, rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, polyarticular juvenile idiopathic arthritis, active enthesitis-related arthritis, hidradenitis suppurativa, non-infectious uveitis |
licensing
- biosimilar/monoclonal antibody/TNF alpha inhibitor. Adalimumab is a monoclonal antibody that binds specifically to TNF alpha and blocks its interaction with cell surface TNF receptors. It is used to treat many conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.
|
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases - Dermatological diseases |
Licensing agreement |
| 2018-10-18 |
Abbvie (USA - IL) Fresenius Kabi (Germany) |
MSB11022 - biosimilar version of Humira® (adalimumab) |
|
licensing |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases |
Licensing agreement |
| 2018-10-18 |
Iovance Biotherapeutics (USA - CA) MaSTherCell (Belgium), a Orgenesis' subsidiary (USA - NY) |
tumor infiltrating lymphocyte (TIL) |
|
- manufaturing - bioproduction
|
Technology - Services |
Production agreement |
| 2018-10-18 |
Xyphos Biosciences (USA - CA) The Parker Institute for Cancer Immunotherapy (USA - CA) |
universal CAR-T therapies based on convertibleCAR’® platform |
|
collaboration |
Cancer - Oncology |
Collaboration agreement |
| 2018-10-17 |
Recombinetics (USA - MN) Mayo Clinic (USA - MN) |
regenerative stem cell therapies |
|
research - development - R&D |
Technology - Services - Regenerative medicine |
Research agreement |
| 2018-10-16 |
Biomarin Pharmaceutical (USA - CA) Medivation (USA - CA), now Pfizer (USA - NY) |
talazoparib (BMN 673) |
metastatic breast cancer. |
product acquisition |
Cancer - Oncology |
Milestone |
| 2018-10-16 |
Ziopharm Oncology (USA - MA) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-10-15 |
Medivir (Sweden) |
|
|
nomination - restructuration |
Infectious diseases |
Restructuring |
| 2018-10-15 |
Sarepta Therapeutics (USA - MA) Lysogene (France) |
LYS-SAF302 |
mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) |
licensing |
Rare diseases - Genetic diseases |
Licensing agreement |
| 2018-10-10 |
Ionis Pharmaceuticals (USA - CA) Roche (Switzerland) |
IONIS-FB-LRx |
complement-mediated diseases including geographic atrophy |
development |
Ophtalmological diseases |
Development agreement |
| 2018-10-09 |
Iris Pharma (France) Keen Eye (France) |
artificial intelligence (AI) applications for bioimaging analysis |
ophtalmological diseases |
collaboration |
Ophtalmological diseases - Technology - Services |
Collaboration agreement |
| 2018-10-09 |
ERS Genomics (Ireland) GenAhead Bio (Japan) |
CRISPR/Cas9 genome editing technology patents |
|
licensing |
Technology - Services |
Licensing agreement |
| 2018-10-09 |
Ziopharm Oncology (USA - MA) Precigen (USA - MD) |
Sleeping Beauty |
|
licensing |
Cancer - Oncology |
Licensing agreement |
| 2018-10-08 |
Sarepta Therapeutics (USA - MA) Paragon Bioservices (USA - MD) |
manufacturing platform for gene therapy programs |
|
manufacturing - bioproduction |
Rare diseases - Genetic diseases - Technology - Services |
Production agreement |
| 2018-10-08 |
eTheRNA immunotherapies (Belgium) |
mRNA manufacturing facility |
|
opening of new premises |
Cancer - Oncology - Technology - Services |
Opening of new premises |
| 2018-10-08 |
Vivebiotech (Spain) undisclosed European hospitals - undisclosed Norwegian company |
lentivirus |
cancers, undisclosed rare disease |
services contract |
Technology - Services |
Services contract |
| 2018-10-08 |
Cytosen Therapeutics (USA - TX) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-10-05 |
Oxford Biomedica (UK) Orchard Therapeutics (UK) |
lentiviral vectors for ex-vivo gene therapy products in primary immune deficiency disorders and inherited metabolic disorders |
adenosine deaminase severe combined immunodeficiency (ADA-SCID), mucopolysaccharidosis-IIIA (MPS-IIIA or Sanfilippo Syndrome type A), undisclosed follow-on indications. |
collaboration |
Rare diseases - Genetic diseases |
Licensing agreement |
| 2018-10-05 |
Sarepta Therapeutics (USA - MA) Nationwide Children’s Hospital (USA - OH) |
AAV1 neurotrophin 3 (NT-3) gene therapy |
Charcot-Marie-Tooth (CMT) neuropathies including CMT type 1A |
licensing |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Licensing agreement |
| 2018-10-04 |
Arrowhead Pharmaceuticals (USA - CA) Janssen Pharmaceutical, a J&J Company (USA) |
- ARO-HBV and up to three additional RNA interference (RNAi) therapeutics
|
hepatitis B |
licensing - research |
Infectious diseases |
Licensing agreement |
